The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breastcancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breastcancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday ...